Human umbilical cord blood-derived mesenchymal stem cell transplantation for the treatment of spinal cord injury

Abstract

The aim of the present study was to investigate the effects of human umbilical cord blood-derived mesenchymal stem cell (HUCB-MSC) transplantation on the functional restoration of spinal cord injury (SCI). A total of 46 adult Wistar rats were randomly divided into three groups: Injury (n=15), control (n=15) and transplantation (n=16). A SCI model was established using the modified Allen's method (vulnerating energy, 25 g/cm). The rats in the control and transplantation groups were injected at the site of the injury with physiological saline and HUCB-MSC suspension, respectively. At week one, two and four following treatment, the behavior of the rats was evaluated using the Basso, Beattie, Bresnahan locomotor rating scale. In addition, immunohistochemistry (IHC) was performed on samples from the rats that had been sacrificed four weeks subsequent to the treatment. Recovery of the spinal cord nerve function was identified to be significantly different at week two and four following treatment (P<0.05), and IHC identified that at week four following treatment novel nerve cells were being produced. Thus, transplantation of HUCB-MSCs promoted the recovery of the damaged function of spinal cord nerves in rats with SCI.

Keywords: human umbilical cord blood; mesenchymal stem cells; rat; spinal cord injury; transplantation.

Figure 1

(A) NSE and (B) GFAP expression in the spinal cord of rats in the transplantation group, as detected by IHC staining at week 4 following treatment (A, magnification, ×100; B, magnification, ×400. NSE, neuron-specific enolase; GFAP, glial fibrillary acidic protein; IHC, immunohistochemistry.